• N4-Acetylcytidine in RNA Epigenetics: Workflows & Optimizati

  2026-05-24

  N4-Acetylcytidine enables high-precision RNA modification assays, supporting everything from enzymatic activity screens to in-depth structure-function analyses. Leveraging APExBIO's ultra-pure reagent ensures reproducibility and streamlined troubleshooting for post-transcriptional RNA research.

• 2-APB: Unlocking Calcium Signaling Control for Cell Fate Ass

  2026-05-23

  2-APB (2-aminoethoxydiphenyl borate) empowers precise modulation of intracellular calcium dynamics, enabling robust studies of autophagy-apoptosis transitions and ER stress responses. This guide translates innovative reference findings and protocol optimization into actionable workflows for advanced cell signaling research.

• Meropenem Trihydrate: Advanced Workflows for Resistance Stud

  2026-05-22

  Meropenem trihydrate stands out as a cornerstone for antibiotic resistance and infection research, enabling both mechanistic investigation and translational innovation. This guide details optimized protocols, metabolomics-driven approaches, and troubleshooting strategies to unlock the full research potential of this leading carbapenem antibiotic.

• Neuroligin 1 Loss Drives Striatal D2-MSN Hyperactivity in AS

  2026-05-22

  This study uncovers how Neuroligin 1 deficiency in striatal D2 receptor-expressing medium spiny neurons leads to hyperactivity and excessive repetitive behaviors, modeling core autism spectrum disorder (ASD) symptoms. The findings clarify molecular and circuit mechanisms underlying RRBs and propose kinase modulation as a potential intervention point.

• U-73122: Precision Phospholipase C Inhibitor for Signaling S

  2026-05-21

  U-73122 stands out as a highly selective phospholipase C inhibitor, enabling researchers to dissect PLC-β2-driven calcium signaling and chemotaxis with unmatched specificity. Its robust performance in both in vitro and in vivo models provides scientists with a powerful tool for unraveling mechanisms of inflammation, apoptosis, and cancer invasion.

• GW4064: Non-Steroidal FXR Agonist for Metabolic & Fibrosis R

  2026-05-21

  GW4064 stands out as a potent, selective non-steroidal FXR agonist pivotal for dissecting complex metabolic and fibrotic pathways. This guide translates breakthrough experimental findings into actionable protocols, troubleshooting strategies, and advanced applications, empowering researchers to leverage GW4064 for next-generation studies in lipid, bile acid, and fibrotic signaling.

• Degarelix Acetate in Prostate Cancer: Rapid Castration Witho

  2026-05-20

  The referenced study provides a comprehensive evaluation of degarelix acetate, a third-generation GnRH antagonist, for advanced prostate cancer. Its key innovation is the ability to achieve rapid testosterone suppression without the surge seen in agonist therapies, offering improved safety and therapeutic kinetics.

• FXR-KLF11 Axis Suppresses JAK2/STAT3 in CI-AKI: Mechanistic

  2026-05-20

  This study demonstrates that activating the FXR-KLF11 axis confers renal protection in contrast-induced acute kidney injury (CI-AKI) by suppressing the JAK2/STAT3 pathway. These findings offer mechanistic clarity and highlight FXR agonists as promising candidates for CI-AKI prevention.

• Degarelix Acetate: Precision GnRH Receptor Antagonist Workfl

  2026-05-19

  Degarelix acetate, a highly selective GnRH receptor antagonist, enables rapid and robust hormone suppression for advanced prostate cancer research and pituitary hormone regulation studies. Learn how to optimize experimental workflows, leverage clinical insights, and troubleshoot common issues for reproducible, high-impact data.

• USP7 Regulates Macrophage Polarization via PKM2 in SAP

  2026-05-19

  This study elucidates how ubiquitin-specific protease 7 (USP7) promotes pro-inflammatory macrophage polarization during severe acute pancreatitis (SAP) by modulating PKM2-driven metabolic reprogramming. The findings demonstrate that targeting the USP7–PKM2 axis offers a mechanistic foundation for metabolic intervention in SAP and highlights novel opportunities for immunometabolic research.

• SC 79: A Specific Small Molecule Akt Activator for Neuroprot

  2026-05-18

  SC 79 is a potent and selective small molecule Akt activator that enables cytosolic phosphorylation of Akt, supporting neuroprotection in ischemic stroke models. Its unique mechanism, robust in vivo efficacy, and validated safety profile make it a valuable research tool for Akt signaling pathway research and neuronal survival studies.

• HDAC Inhibition Reverses EBV-Induced Plasticity in NPC

  2026-05-18

  This study elucidates how Epstein-Barr virus (EBV) drives dedifferentiation in nasopharyngeal carcinoma (NPC) via LMP1-mediated recruitment of HDACs, resulting in transcriptional repression of CEBPA. The work demonstrates that HDAC inhibition can restore differentiation markers and reduce stem-like properties in NPC, advancing the rationale for epigenetic differentiation therapy in solid tumors.

• Digoxin in Translational Research: Beyond Cardiac Boundaries

  2026-05-17

  This thought-leadership article explores Digoxin’s evolving role in translational research, integrating mechanistic insight, cross-domain antiviral evidence, and strategic guidance. We dissect its Na+/K+ ATPase pump inhibition, highlight competitive and workflow advantages, cite clinical and preclinical benchmarks, and articulate how APExBIO’s high-purity Digoxin empowers next-generation experimental design. The article provides actionable protocol parameters, contextualizes limitations, and projects a visionary yet evidence-based outlook.

• Dimethyloxalylglycine (DMOG): Technical Guide and Protocols

  2026-05-16

  Dimethyloxalylglycine (DMOG) enables precise and reversible stabilization of hypoxia-inducible factors for hypoxia signaling and inflammation research. Researchers can use DMOG to model hypoxic responses in both in vitro and in vivo experiments, but it should not be used for diagnostic or therapeutic purposes. Rigorous attention to solubility, storage, and workflow parameters is essential for consistent results.

• Phosphatase Inhibitor Cocktail (2 Tubes, 100X): Precision in

  2026-05-15

  The Phosphatase Inhibitor Cocktail (2 Tubes, 100X) delivers robust protein phosphatase 1 and 2A inhibition, preserving phosphorylation states during sample preparation. Its dual-component formulation enables comprehensive inhibition of serine/threonine and tyrosine phosphatases, supporting reproducible results in immunoblotting, kinase activity assays, and mass spectrometry. APExBIO’s validated design ensures stability and workflow compatibility for high-fidelity phosphoproteomics.

450 records 17/30 page Previous Next First page 上5页 1617181920 下5页 Last page